Entropy Neurodynamics (ASX:ENP)
ASX announcement history & article coverage
Transparent by design.
Announcments by Entropy Neurodynamics (ASX:ENP) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Change of Director's Interest Notice - HJ
Cleansing Notice
Application for quotation of securities - ENP
TRP-8803 60-Minute Infusion Achieved in Phase 2 BED Study
Entropy begins six-patient test of 60-minute TRP-8803 infusion in Phase 2 binge eating disorder study
2026 AGM Notice of Meeting, Letter of Access and Proxy
Notification regarding unquoted securities - ENP
Notification of Date of 2026 AGM
All Patients Improve, 50% Achieve 12-Week BED Remission
TRP-8803 BED results show durable clinical improvement at 12 weeks
Investor Webinar Presentation
Appendix 4G and Corporate Governance Statement
Appendix 4E and 2026 Annual Report
Entropy Neurodynamics reports improved FY26 results and promising clinical progress with TRP-8803 in Binge Eating Disorder
Entropy Advances TRP-8803 to US Phase 2 in Depression
Application for quotation of securities - ENP
Trading Halt
TRP 8803 manufacturing secured for Phase 2/3 advancement
Entropy Neurodynamics partners with BioCina for GMP manufacturing of TRP-8803 psilocin formulation
Change of Director's Interest Notice - HJ
Cleansing Notice
Application for quotation of securities - ENP
BioShares 2026 Investor Presentation Deck
72-Patient Trial Fast-Tracks TRP-8803 Commercialisation
Trading Halt
Techknow Invest Roadshow presentation
Appointment of Joint Company Secretary
Quarterly Activities Report and Appendix 4C
Entropy Neurodynamics reports strong Phase 2 clinical results in BED and IBS, advances TRP-8803 development and IP portfolio
South Africa Grants ENP Broad Fibromyalgia Patent to 2043
Entropy Neurodynamics granted South African patent for psilocybin fibromyalgia treatment